NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Axsome Therapeutics, Inc. (AXSM) Stock Analysis

Axsome Therapeutics, Inc. (AXSM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AXSM

$206.68

−$1.67 (−0.80%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AXSM with… →

AXSM Key Statistics

As of Sep 4, 2026
Trading
Open
$207.01
Previous Close
$208.35
Day's Range
205.49–208.51
52-Week Range
112.90–260.19
Volume
438.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.71
Valuation
Market Cap
$10.83B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
41.06
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.94
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.72
Financials (FY)
Revenue (FY)
$638.50M+65.55%
Net Income (FY)
−$183.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
−24.68%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
52.38M
1-Year Return
+66.13%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
849.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AXSM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.16%
2025+115.86%
2024+6.31%
2023+3.19%
2022+104.16%
2021−53.63%
2020−21.18%
2019+3565.25%
2018−49.64%
2017−17.04%
2016 (partial year)−12.34%

As of September 4, 2026.

AXSM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$638.50M−$183.17M−28.7%
2024$385.69M−$287.22M−74.5%
2023$270.60M−$239.24M−88.4%
2022$50.04M−$187.13M−374.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$638.50M$591.02M−$169.24M−$183.17M−28.7%
2024$385.69M$352.39M−$252.44M−$287.22M−74.5%
2023$270.60M$244.54M−$182.91M−$239.24M−88.4%
2022$50.04M$44.84M−$176.50M−$187.13M−374.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AXSM Valuation vs Biotechnology Median

Median of 656 stocks
MetricAXSMBiotechnology medianvs median
P/S ratio13.9415.269% below
Profit margin−24.68%0.00%24.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Axsome Therapeutics, Inc. (AXSM) at $10.83B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1,346.

Over the past 52 weeks the price has ranged from $112.90 to $260.19. AXSM last closed at $206.68 on September 4, 2026. That is −$1.67 (−0.80%) against the previous close. The latest close sits 83.06% above that 52-week low.

Financial Health

In fiscal 2025, Axsome Therapeutics, Inc. reported revenue of $638.50M. Against the prior fiscal year total of $385.69M, that is a change of +65.55%. The same year closed with a net loss of $183.17M. The reported profit margin is −24.68%. That is 24.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −3.72.

Across the 4 fiscal years on file, revenue moves from $50.04M in 2022 to $638.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 41.06. The price-to-sales ratio is 13.94. On price-to-sales that is 8.67% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +66.13%. Measured over 10 years, that is +39.76% a year compounded. Beta against the wider market is reported at 0.71. Annualized volatility over the trailing 10 years is 90.35%.

Growth & Income

The record shows no dividend for AXSM.

The strongest complete calendar year on file is 2019 at +3,565.25%; the weakest is 2021 at −53.63%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +13.16% year to date.

Peer Comparison

Axsome Therapeutics, Inc. (AXSM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Axsome Therapeutics, Inc. AXSM $10.83B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Axsome Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Visit website →